

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ALGORAE PHARMACEUTICALS LIMITED</b>
<b>ABN</b>	<b>14 104 028 042</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	MR BRADLEY ROLAND LATHAM
<b>Date of last notice</b>	5 July 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	09 November 2023
<b>No. of securities held prior to change</b>	10,000,000 Ordinary Shares.
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	5,000,000 Performance Rights A 5,000,000 Performance Rights B 5,000,000 Performance Rights C 5,000,000 Performance Rights D
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	10,000,000 Ordinary Shares 5,000,000 Performance Rights A 5,000,000 Performance Rights B 5,000,000 Performance Rights C 5,000,000 Performance Rights D
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of Performance Rights, as approved by Shareholders

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If prior written clearance was provided, on what date was this provided?</b>	
---	--

**Algorae Pharmaceuticals Limited**

ABN: 14 104 028 042  
ASX: 1AI  
OTCQB: LVCLY

10 November 2023

**Section 708A Cleansing Statement - Amended**

This notice is given by Algorae Pharmaceuticals Limited (Company) under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

The Company hereby confirms that:

- a) the Company has issued on 8 November 2023:
  - i. 500,000 fully paid ordinary shares at a deemed issue price of \$0.016 per share;
  - ii. 25,000,000 Performance Rights A in accordance with Shareholder Approval;
  - iii. 25,000,000 Performance Rights B in accordance with Shareholder Approval;
  - iv. 25,000,000 Performance Rights C in accordance with Shareholder Approval; and
  - v. 25,000,000 Performance Rights D in accordance with Shareholder Approval.
- b) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations, Act;
- c) As a disclosing entity the company is subject to regular reporting and disclosure obligations;
- d) As at the date of this notice the Company has complied with:
  - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - ii. section 674 of the Corporations Act as it applies to the Company; and
- e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

Yours Sincerely,



**Madhukar Bhalla**

**Company Secretary**